Short Communication:Low Prevalence of Genotypic Drug Resistance Mutations among Antiretroviral-Naive HIV Type 1 Patients in Malaysia
- 1 February 2006
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 22 (2) , 121-124
- https://doi.org/10.1089/aid.2006.22.121
Abstract
To assess the prevalence of mutations associated with drug resistance in antiretroviral-naive patients in Kuala Lumpur, Malaysia, genotypic resistance testing was conducted among drug-naive HIV-1 patients attending the University Malaya Medical Center (UMMC) between July 2003 and June 2004. Reverse transcriptase (RT) and protease genes of plasma virions were sequenced from 100 individuals. The majority of the patients were recently diagnosed. Codons 20–255 of the RT and 1–96 of the protease gene were examined for major and minor mutations associated with antiretroviral resistance reported by the International AIDS Society- USA (IAS-USA) Drug Resistance Mutations Group. The prevalence of patients with at least one major mutation conferring drug resistance was 1%, with only one patient having a Y181C amino acid substitution in the RT gene that confers high-level resistance to nevirapine and delavirdine. Minor mutations were detected in high prevalence in the protease gene. Amino acid substitutions I13V, E35D, and M36I were associated with CRF01_AE while L63P, V77I, and I93L were associated with subtype B. Baseline prevalence of major mutations associated with resistance to antiretroviral drugs was low among antiretroviral-naive HIV-1 patients, suggesting that routine drug resistance testing may be unnecessary for all individuals newly diagnosed with HIV or all patients beginning antiretroviral therapy.Keywords
This publication has 23 references indexed in Scilit:
- Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypesJournal of Clinical Virology, 2004
- The Epidemiology of Antiretroviral Drug Resistance among Drug‐Naive HIV‐1–Infected Persons in 10 US CitiesThe Journal of Infectious Diseases, 2004
- Comparison of Nevirapine (NVP) Resistance in Ugandan Women 7 Days vs. 6–8 Weeks after Single-Dose NVP Prophylaxis: HIVNET 012AIDS Research and Human Retroviruses, 2004
- Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet)AIDS, 2003
- A Major Role for a Set of Non-Active Site Mutations in the Development of HIV-1 Protease Drug ResistanceBiochemistry, 2003
- Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome.The Journal of Infectious Diseases, 2002
- Mutations associated with genotypic resistance to antiretroviral therapy in treatment naı̈ve HIV-1 infected patients in GreeceVirus Research, 2002
- Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary InfectionJournal of Virology, 2002
- Secondary Mutations in the Protease Region of Human Immunodeficiency Virus and Virologic Failure in Drug‐Naive Patients Treated with Protease Inhibitor–Based TherapyThe Journal of Infectious Diseases, 2001
- Primary Infection with Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Does Not Adversely Affect Outcome at 1 YearThe Journal of Infectious Diseases, 1996